肝脓肿在重症监护病房的预后(POLAIR):一项多中心观察性研究
该多中心回顾性研究纳入法国24个ICU于2010年1月至2020年12月收治的335例成人肝脓肿患者,中位年龄66岁,68%为男性,58%因脓毒性休克入ICU。ICU病死率11.6%,多因素分析显示SOFA评分(HR 3.45 [1.95-6.09],p<0.001)和门静脉血栓(HR 3.14 [1.54-6.39],p=0.001)是死亡的显著危险因素。引流与短期生存改善无关(HR 1.22 [0.65-2.72],p=0.52)。在按门静脉血栓混杂因素匹配的人群中,较高的SOFA评分是唯一与死亡相关的因素(HR 3.11 [1.76-5.49],p=0.001)。作者认为需要前瞻性研究改善管理策略,引流的生存获益尚不明确。
要点
- 肝脓肿入住ICU患者病死率11.6%,SOFA评分是死亡的独立危险因素(HR 3.45 [1.95-6.09],p<0.001)。
- 门静脉血栓是死亡的独立危险因素(HR 3.14 [1.54-6.39],p=0.001),13.4%的患者存在门静脉血栓。
- 引流与短期生存改善无关(HR 1.22 [0.65-2.72],p=0.52),62%的患者接受引流。
- 脓毒性休克是入住ICU的主要原因(58%),62%的患者需要血管升压药,29%需要机械通气。
- 在按门静脉血栓混杂因素匹配的人群中,较高的SOFA评分是唯一与死亡相关的因素(HR 3.11 [1.76-5.49],p=0.001)。
适用人群与场景
- 法国24个ICU于2010年1月至2020年12月收治的成人肝脓肿患者,共335例。
- 中位年龄66岁[53-73],68%为男性,合并症包括糖尿病(29.9%)和癌症或血液系统疾病。
- 脓毒性休克是入住ICU的主要原因(58%)。
处置流程与药物剂量
- 62%的患者接受引流,其中40%在48小时内完成引流。
- 抗生素治疗中位疗程35天[21-42]。
- 62%的患者需要血管升压药,29%需要机械通气。
研究设计与关键结果
- 多中心回顾性研究,纳入法国24个ICU的335例成人肝脓肿患者,中位年龄66岁[53-73],68%为男性。
- ICU入院时中位SAPS2评分42[31-53],SOFA评分6[3-9];脓毒性休克是入住ICU的主要原因(58%)。
- 肝脓肿 putative 来源:胆源性31%,隐源性40%;60%为单发,38.8%累及右叶,中位直径67 mm[47-91];门静脉血栓占13.4%。
- 微生物学资料获得率82%:革兰阴性杆菌59.7%(主要为大肠埃希菌19.6%和克雷伯菌属19.1%),革兰阳性球菌29.6%(主要为链球菌属17.1%)。
- ICU病死率11.6%;多因素分析显示SOFA评分(HR 3.45 [1.95-6.09],p<0.001)和门静脉血栓(HR 3.14 [1.54-6.39],p=0.001)是死亡的显著危险因素。
- 引流与短期生存改善无关(HR 1.22 [0.65-2.72],p=0.52);在按门静脉血栓混杂因素匹配的人群中,较高的SOFA评分是唯一与死亡相关的因素(HR 3.11 [1.76-5.49],p=0.001)。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要前瞻性研究改善管理策略,因为引流的生存获益尚不明确。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Liver abscess (LA) is a rare but potentially serious condition with a high mortality rate. Current epidemiological data of LA patients requiring intensive care unit (ICU) admission are limited.
METHODS: This multicentre retrospective study included adults admitted to 24 ICUs in France between January 2010 and December 2020. Risk factors for mortality were identified by multivariate analysis. A propensity score was used to adjust for confounders related to the presence of portal vein thrombosis.
RESULTS: 335 patients were enrolled. The median age was 66 years [53-73] and 68% were male. Commons comorbidities included diabetes (29.9%) and cancer or haematological disease. Septic shock was the main reason for admission (58%). The median SAPS2 score at ICU admission was 42 [31-53] and the SOFA score was 6 [3-9]. The putative origin of LA was biliary (31%), while 40% were cryptogenic. Most patients (60%) had a solitary LA, involving the right lobe (38.8%), with a median diameter of 67 mm [47-91]. Associated portal vein thrombosis (PVT) was present in 13.4% of cases. Microbiological documentation was obtained in 82% of patients, showing gram-negative bacilli (59.7%), mainly Escherichia coli (19.6%) and Klebsiella spp. (19.1%), and gram-positive cocci (29.6%), mainly Streptococcus spp. (17.1%). Drainage was performed in 62% of cases, 40% within 48 h. The median duration of antibiotic therapy was 35 days [21-42]. During hospitalisation, 62% of patients required vasopressors and 29% required mechanical ventilation. In-ICU mortality was 11.6%. Multivariate analysis showed that organ dysfunction illustrated by SOFA score (HR 3.45 [1.95-6.09], p < 0.001) and PVT (HR 3.14 [1.54-6.39], p = 0.001) were significant risk factors for mortality. Drainage was not associated with improved short-term survival (HR 1.22 [0.65-2.72], p = 0.52). In the population matched for PVT confounders, a higher sofa score was the only factor associated with mortality (HR 3.11 [1.76-5.49] IC95%, p = 0.001).
CONCLUSIONS: This multicentre study illustrates the severity of LA in French intensive care units and identifies organ dysfunction (SOFA score) and portal vein thrombosis as major risk factors for mortality. Prospective studies are needed to improve management strategies, as the survival benefit of drainage is unclear.
参考来源
- Le Goff M, Martino F, Rossi G, et al. Prognosis of liver abscess in the intensive care unit (POLAIR), a multicentre observational study. Crit Care. 2025. PMID: 40197508. doi:10.1186/s13054-025-05376-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。